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The heart is the most common site of congenital
defects, and valvuloseptal defects are themost com-
mon of the cardiac anomalies seen in the newborn.
The process of endothelial-to-mesenchymal transi-
tion (EndMT) in the cardiac cushions is a required
step during early valve development, and Notch
signaling is required for this process. Here we show
that Notch activation induces the transcription of
both subunits of the soluble guanylyl cyclase (sGC)
heterodimer, GUCY1A3 and GUCY1B3, which form
the nitric oxide receptor. In parallel, Notch also pro-
motes nitric oxide (NO) production by inducing Acti-
vin A, thereby activating a PI3-kinase/Akt pathway
to phosphorylate eNOS. We thus show that the
activation of sGC by NO through a Notch-dependent
autocrine loop is necessary to drive early EndMT in
the developing atrioventricular canal (AVC).
INTRODUCTION
During cardiac development, the linear heart tube loops right-
ward at embryonic day (E) 8.5 to initiate the establishment of
a four-chambered structure (E9.0–9.5) consisting of paired left
and right atria, and ventricles. In order to separate the chambers,
swellings composed of extracellular matrix in the atrioventricular
canal (AVC) and the outflow tract, referred to as cardiac cush-
ions, become populated by mesenchymal cells generated from
the overlying endocardium. This process called endothelial-
to-mesenchymal transition (EndMT) commences at E9.5 in the
AVC, resulting in endocardial cells (ECs) delaminating from the
monolayer and invading the underlying matrix (Camenisch
et al., 2002). Following remodeling, the cushions eventually288 Developmental Cell 21, 288–300, August 16, 2011 ª2011 Elseviedevelop into the cardiac valves and the membranous septum
of the adult heart (Eisenberg and Markwald, 1995; Niessen and
Karsan, 2008).
Several signaling pathways coordinate to initiate and poten-
tiate EndMT, with the Notch pathway being a central player in
the process (Niessen and Karsan, 2008; Timmerman et al.,
2004). Notch proteins are a family of transmembrane receptors
(Notch1–4 in mammals) that are activated upon binding byNotch
ligands: Jagged (Jag) 1 and 2 and Delta-like (Dll) 1, 3, and 4.
Upon activation, Notch receptors undergo proteolytic process-
ing, and the intracellular domain of Notch (NICD) is released
from its membrane tether. The NICD then translocates to the
nucleus, binds to the DNA-binding corepressor RBPJ (recombi-
nation signal-binding protein for immunoglobulin k J region),
and recruits the coactivator MAML1 (Mastermind-like 1), to
derepress and activate transcription of downstream target
genes such as the HES and HEY family of transcription factors
(Iso et al., 2003). Deletion of Notch1 or Rbpj in mice results in
malformation of the cardiac cushions (Timmerman et al., 2004).
Deletion of the Notch target gene Hey2, or double deletion of
Hey1 and Hey2 or Hey1 and HeyL, results in various congenital
heart defects, including cardiac cushion defects (Donovan
et al., 2002; Fischer et al., 2004, 2007). Mutations of Notch1
are associated with nonsyndromic valvular disease such as
bicuspid aortic valves, as well as with more severe cardiac
anomalies (Garg et al., 2005). Mutations in Jag1 have been
implicated in Alagille syndrome, an entity that comprises a spec-
trum of defects including pulmonary artery stenosis, tetralogy of
Fallot, and additional valvular anomalies (Eldadah et al., 2001;
Li et al., 1997; Oda et al., 1997).
Nitric oxide (NO) has also been shown to play a role in
cardiac function (Fukumura et al., 2006; Rastaldo et al., 2007),
blood pressure homeostasis (Sessa, 2009), and epithelial-
mesenchymal transition (Vyas-Read et al., 2007). NO is gener-
ated by nitric oxide synthases (NOSs), of which there are three
isoforms: endothelial (eNOS, or NOS3), inducible (iNOS, or
NOS2) and neuronal (nNOS, or NOS1). External signals (shearr Inc.
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ylation events that can either activate (Ser114 and Ser1177) or
inhibit (Thr485) eNOS (Mount et al., 2007). Similar to heterozy-
gous NOTCH1 mutations in human (Garg et al., 2005), homozy-
gous eNOS knockout mice also display bicuspid aortic valves
and other major cardiac anomalies (Aicher et al., 2007; Feng
et al., 2002; Lee et al., 2000). Of the three classes of type III
guanylyl cyclases (GCs), NO signaling is propagated through
the soluble GC (sGC) heterodimer (Baker and Kelly, 2004;
Yamagami and Suzuki, 2005), which consists of an a sub-
unit (GUCY1A2 or GUCY1A3) and a b subunit (GUCY1B3).
GUCY1A3/1B3 is expressed in most tissues, whereas
GUCY1A2/1B3 is predominantly found in the brain (Giuili et al.,
1992; Mergia et al., 2003). Activation of sGC leads to production
of the second messenger 30, 50 cyclic guanosine monophos-
phate (cGMP), which results in smooth muscle cell relaxation
by blocking calcium influx and dephosphorylation of myosin light
chains (Ignarro et al., 1986; Murad, 1986). In addition to blood
pressure regulation, sGC proteins have also been shown to
promote endothelial cell survival and migration (Pyriochou
et al., 2006; Pyriochou et al., 2007a, 2007b).
In this study we demonstrate that Notch induces activation of
the NO-sGC axis through an autocrine loop during EndMT in
the AVC. The promoters of both GUCY1A3 and GUCY1B3
are bound by RBPJ, and transcription is induced upon Notch
activation. Inhibition of Notch specifically in endocardial cells
in vivo inhibits EndMT and decreases Gucy1b3 expression.
Similarly, sGC inhibition blocks EndMT in AVC explants and
decreases cushion cellularization at E9.5 and E10.5 in vivo.
Concomitant with upregulation of the GUCY genes, Notch
induces Activin A, which in turn activates PI3K and Akt in
a paracrine fashion followed by downstream eNOS activation
and NO production. Here we show that Notch signaling
increases NO production simultaneously with induction of the
NO receptor sGC, and this pathway contributes to EndMT in
the AVC.
RESULTS
GUCY1A3 and GUCY1B3 Are Notch Target Genes
To identify Notch target genes in the AVC endocardium during
heart development, we compared two microarray data sets
with AVC transcriptome libraries. Transcripts induced by at
least 2-fold in NICD-transduced human umbilical vein endothe-
lial cells (HUVECs; this study), and in Dll4-activated HUVEC
(Harrington et al., 2008), were compared with mRNA expressed
in the AVC at E9.5, E10.5, and E11.5 as determined by Serial
Analysis of Gene Expression (SAGE) (Siddiqui et al., 2005;
Vrljicak et al., 2010). Of the 24 candidate genes identified (see
Figure S1A available online), 11 transcripts were upregulated in
human ECs transduced with Notch ligands (Jag1 or Dll4) or
NICD compared to the empty vector control using reverse
transcription-quantitative polymerase chain reaction (RT-
qPCR) (Table S1).
Of the 11 validated candidates, 5 have been reported to be
associated with heart development, EndMT, or are regulated
by Notch signaling (Hey1, Jag1, SDC1, SDC2, and SNAI2)
(Arrington and Yost, 2009; Fischer et al., 2004, 2007; High
et al., 2008b; Niessen et al., 2008; Sun et al., 1998). Of the re-Developmaining six candidates,GUCY1A3 andGUCY1B3were selected
for further study because both genes are highly induced by
Notch signaling (Table S1) and heterodimerize to form the
soluble NO receptor, sGC. RT-qPCR showed that Notch activa-
tion by ligand-induced activation (Jag1, Dll4) or enforced expres-
sion of NICD increased GUCY1A3 mRNA levels 316 ± 43, 18 ±
1.5, and 313 ± 43.8-fold, respectively, and GUCY1B3 mRNA
levels by 154 ± 3.2, 13.4 ± 1.7, and 282 ± 37.2-fold, respectively
(Figure 1A). As a positive control, we confirmed that the known
Notch target gene HEY1 was also induced by Notch activation
(Figure 1A). Induction of GUCY1A3 and GUCY1B3 mRNA was
abolished when Jag1- or Dll4-expressing ECs were treated
with the g-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-l-
alanyl]-S-phenylglycine t-butyl ester (DAPT) (Figure 1B), thus
confirming Notch-dependent induction.
To determine whether the ligand-expressing or Notch-
activated cells induce sGC, ligand-expressing Jag1 or Dll4
(YFP+) was cocultured with parental ECs (YFP) and flow sorted
after 48 hr into YFP+ (ligand-expressing cells) and YFP (parental
cells) populations, and each population was analyzed by
RT-qPCR. As noted by induction of ACTA2 and HEY1 (Figure
1C), Notch activation occurs mainly in the parental cells in this
coculture system. The major induction of GUCY1A3 and
GUCY1B3mRNA levels also occurred in the YFP parental cells
(Figure 1D), consistent with the notion that GUCY1A3 and
GUCY1B3 are induced by Notch activation. Although TGFb
signaling plays a crucial role in AVC development (Camenisch
et al., 2002), TGFb1 stimulation had little effect on GUCY1A3
and GUCY1B3 expression, and did not synergize with Notch
activation to induce sGC components (Figure S1B).
Analysis of the human and mouse GUCY1A3 and GUCY1B3
promoters (from 1.5 kb upstream of the transcriptional start
site [TSS] to the end of intron 1) revealed several putative
RBPJ-binding sites (Figure S1C). Five putative RBPJ-binding
sites were identified in the humanGUCY1B3 promoter, and three
of these sites were conserved in the mouse, while only one
conserved putative RBPJ-binding site was noted between the
human and murine GUCY1A3 promoters. Chromatin immuno-
precipitation (ChIP) followed by qPCR with primers flanking the
RBPJ elements demonstrated that RBPJ bound all three
conserved RBPJ consensus motifs in the human GUCY1B3
promoter (1065, 6.7 ± 2.1-fold; 37, 2.6 ± 0.4-fold; +247,
3.4 ± 0.9-fold) as well as the single conserved RBPJ consensus
motif in the human GUCY1A3 promoter (944, 4.4 ± 1.7-fold)
(Figure 1E) in ECs transduced with Flag-tagged RBPJ. As a posi-
tive control, we showed RBPJ binding to the human HEY1
promoter located 180 bp upstream of the TSS (Figure 1E). As
a negative control, we used the ZNF3 promoter, which lacks
a consensus RBPJ-binding motif (Figure 1E). Immunoblotting
of ECs activated by NICD, Jag1, or Dll4 showed that Notch
activation induced GUCY1B3 protein (Figure 1F), and the
induction was abolished when RBPJ was knocked down (Fig-
ure 1G). Thus, GUCY1A3 and GUCY1B3 are Notch target genes
activated by an RBPJ-dependent mechanism.
To demonstrate thatGucy1b3 is a target gene of Notch in vivo,
an EC-specific Tet-inducible binary transgenic mouse model
was used where expression of a pan-Notch inhibitor, domi-
nant-negative (dn)-MAML fused to GFP behind the TetOS
promoter, is driven by the VE-cadherin promoter (VEtTA) in themental Cell 21, 288–300, August 16, 2011 ª2011 Elsevier Inc. 289
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Figure 1. Notch Signaling Induces GUCY1A3 and GUCY1B3 Expression through RBPJ
(A and B) Expression ofGUCY1A3 andGUCY1B3 (see Figure S1) was induced (A) as determined by RT-qPCR in ECs transduced with Jag1, Dll4, NICD, or empty
vector, but blocked (B) by the g-secretase inhibitor, DAPT (10 mM), compared to vehicle (DMSO). Data are shown as fold enrichment over the empty vector control
(n = 3; *p = 0.05, **p = 0.001).
(C and D) Parental ECs (YFP) cocultured with Notch ligands (YFP+) for 48 hr were flow sorted for YFP expression and analyzed by RT-qPCR for expression of
ACTA2 and HEY1 (C), orGUCY1A3 andGUCY1B3 (D) in the YFP+ (ligand-expressing) and YFP (parental ECs) cells. Data are shown as fold enrichment over the
empty vector control (n = 3; *p = 0.05).
(E) RBPJ occupancy of conserved RBPJ-binding sites of humanGUCY1B3 andGUCY1A3 promoters (Figure S2B) was examined by anti-Flag ChIPwith IgGChIP
used as a negative control in ECs transduced with either Flag-RBPJ or empty vector. qPCR of the immunoprecipitated DNA was conducted using primers
flanking the conserved RBPJ-binding sites. Fold enrichment was calculated by normalizing to input DNA and then referencing to empty vector anti-Flag ChIP
(n = 5; *p = 0.05).
(F) Cell lysates from ECs transduced with Jag1 (J), Dll4 (D), NICD (N), or empty vector (M) were immunoblotted for GUCY1B3 protein.
(G) Notch-activated cells were lentivirally transduced with shRBPJ-A, shRBPJ-B, or shRandom (control) and immunoblotted for GUCY1B3 and RBPJ protein.
Tubulin expression was used as a loading control.
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Notch Activates the NO Pathway in the AV Canalabsence of tetracycline (Fu et al., 2009). To assay Gucy1b3
protein expression during EndMT, EC Notch inhibition was
induced at E9.5 by withdrawal of tetracycline from the drinking
water, and embryos were collected at E10.5 (VEtTA 3 TetOS-
dnMAML-GFP). In VEtTA3TetOS-dnMAML-GFP E10.5 double-
transgenic hearts, Gucy1b3 protein expression was reduced in
both the endocardium and the mesenchyme of the AVC
compared to single transgenic littermate controls (Figures 2A–
2H). Notch inhibition resulted in an approximately 2-fold re-
duction in the intensity of Gucy1b3 staining in the AVC when
normalized to DAPI staining intensity (1.9 ± 0.2 versus 0.8 ±
0.2; p = 0.02) or to cellularity (number of nuclei, 2.5 ± 0.2 versus
1.4 ± 0.2; p = 0.003). Reduced Gucy1b3 staining was also noted
specifically in the endocardium as determined relative to CD31
staining intensity (1.3 ± 0.1 versus 0.6 ± 0.1; p = 0.005) (Figure 2I).
These results suggest that Gucy1b3 expression is regulated by
Notch in the developing AVC and that inhibition of EC-Notch
signaling blocks Gucy1b3 expression in vivo.
Notch-Induced sGC Drives EndMT
To determine the role of sGC in EndMT, we used an ex vivo AVC
explant model in which E9.5 wild-type AVCs are cultured on
collagen gels, and cellular migration and invasion of the matrix
are quantified 48 hr later (Camenisch et al., 2002; Niessen
et al., 2008). To ensure that the migrating/invading cells com-
prised mesenchymal cells, all explants were also stained with
the mesenchymal marker, SMA, and the areas of SMA and
DAPI staining were correlated (Figure S2). Inhibition of sGC
activity with [1H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one]
(ODQ; 10 mM) resulted in significant blockade of EndMT (p <
0.05), similar to Notch inhibition (DAPT 10 mM; p < 0.05),
compared to vehicle-treated explants (Figure 2J). In contrast,
administration of the NO-independent sGC activator BAY41-
2272 (10 mM) showed marked induction of EndMT (p < 0.05;
Figure 2J). Additionally, knockdown ofGucy1b3 in AVC explants
using lentiviral transduction with two distinct shRNAs targeting
different sequences of Gucy1b3 significantly reduced EndMT
compared to a vector control (p < 0.05) (Figure 2K). To determine
whether sGCactivity is required for cushion cellularization in vivo,
ODQ (50 mg/kg) was administered to pregnant C57Bl/6J mice
intraperitoneally 24 hr prior to embryo isolation. Cushion cellula-
rization was significantly inhibited at E9.5 when ODQ was
administered at E8.5 (vehicle, 43.1 ± 6.6 nuclei/mm2; ODQ,
21.3 ± 6.2 nuclei/mm2; p = 0.02) and at E10.5 with ODQ adminis-
tered at E9.5 (vehicle, 170.5 ± 4.4 nuclei/mm2; ODQ, 149.4 ±
3.7 nuclei/mm2; p = 0.002), but not at E11.5 when EndMT is
complete (vehicle, 270.1 ± 17.5 nuclei/mm2; ODQ, 289.5 ± 14.9
nuclei/mm2) (Figures 2L and 2M). Taken together, these results
demonstrate that sGC activation is required for EndMT during
the initiation of cushion cellularization.
Notch Activates NO Synthesis in a Cell Nonautonomous
Fashion
Given that sGC is activated by NO, we examined whether Notch
also induces NO synthesis in order to activate the sGC pathway
in an autocrine fashion. Enforced expressionofNICDor coculture
of parental ECswith Notch ligand-expressing cells increased NO
production compared to vector-transduced cells, as measured
by accumulation of the NO-reactive dye diaminorhodamine 4M-DevelopAM (DAR4M-AM) (Figure 3A). The majority of NO accumulation
was observed in Notch-activated cells. However, NO accumula-
tion was also noted in the non-Notch-activated ECs, suggesting
a potential paracrine effect of Notch activation. NO inductionwas
abolished when ECs were treated with the pan-NOS inhibitor
Nu-Nitro-L-arginine methyl ester hydrochloride (L-NAME),
thereby confirming the requirement of NOS activity (Figure 3A).
Coculture of parental ECs with Notch Jag1-expressing cells
also increased NO production, as quantified by the Griess reac-
tion (p = 0.002; Figure 3B). To assay for the degree of sGC activa-
tion, we measured cGMP concentration in the cell lysates. Cell
lysates from coculture of parental ECs with Jag1- or Dll4-trans-
duced ECs showed a significant increase in cGMP (0.21 ± 0.06
and 0.26 ± 0.08 cGMP [pmol/ml]/total protein [mg], respectively)
compared to cocultures with the empty vector control (0.07 ±
0.02 cGMP [pmol/ml]/total protein [mg]; p = 0.05) (Figure 3C).
To confirm a paracrine effect of Notch on NO synthesis, ECs
were treated with conditioned medium collected from NICD- or
vector-transduced ECs. Intracellular NO staining with DAR4M-
AM showed accumulation of NO in NICD-conditioned medium-
exposed ECs over time (Figure 3D), with a significant increase
in NO generation, asmeasured by theGriess reaction, compared
to vector-conditioned medium-treated controls following 90 and
120 min of exposure (1.7 ± 0.1 versus 1.4 ± 0.1 mM nitrite/mg
protein [p = 0.05] and 1.8 ± 0.1 versus 1.3 ± 0.1 mM nitrite/mg
protein [p = 0.05], respectively) (Figure 3E). Cell lysates treated
with NICD-conditioned medium also showed a significant
increase in sGC activation as determined by an increase in
cGMP compared to vector-conditioned medium-exposed ECs
following 90 and 120 min of exposure (3.2 ± 1.0 versus 1.1 ±
0.6 cGMP [pmol/ml]/total protein [mg] [p = 0.05], and 3.3 ± 0.7
versus 1.2 ± 0.5 cGMP [pmol/ml]/total protein [mg] [p = 0.05],
respectively) (Figure 3F). Thus, Notch activation induces NO
synthesis in a paracrine fashion to activate sGC.
To observeNOproduction in the developing AVC, DAR4M-AM
(25 mmol/kg) was administered intraperitoneally into pregnant
mice 1 hr prior to embryo isolation. In the AVC, DAR4M-AM
fluorescence was observed in the endocardium and mesen-
chyme at E10.25 and E10.5 (Figure 3G). In contrast, NO was
weakly detectable with DAR4M-AM at E10.25 and E10.5 when
Notch signaling was inhibited, by removal of tetracycline from
the drinking water 24 hr prior in VEtTAxTetOS-dnMAML-GFP
double transgenic embryos compared to littermate controls (Fig-
ure 3G). Quantification of DAR4M-AM staining relative to the
AVC cushion area showed a 2.7- and 5.6-fold decrease of NO
in E10.25 and E10.5 VEtTAxTetOS-dnMAML-GFP AVC
compared to littermate controls (E10.25, 176 ± 24 versus
474 ± 70.9; E10.5, 298 ± 103 versus 53.6 ± 10.7 positive-pixels
normalized to AVC area analyzed [p = 0.002]) (Figure 3H). Quan-
tification of DAR4M-AM staining in the endocardium showed
a 1.3- and 12.8-fold decrease of NO in E10.25 and E10.5 VEt-
TAxTetOS-dnMAML-GFP AVC compared to littermate controls
(E10.25, 0.41 ± 0.006 versus 0.30 ± 0.04; E10.5, 0.66 ± 0.35
versus 0.056 ± 0.02 positive-pixels normalized to endocardial
area [p = 0.05]) (Figure 3I). Taken together, these results demon-
strate that Notch induces NO production in the developing AVC
in a paracrine manner, which is then capable of stimulating the
sGC heterodimer formed by Gucy1a3 and Gucy1b3, in Notch-
activated ECs.mental Cell 21, 288–300, August 16, 2011 ª2011 Elsevier Inc. 291
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Figure 2. Notch-Induced sGC Contributes to the Initiation of EndMT
(A–H) GUCY1B3 (red) and CD31 (green) protein expression was evaluated by immunofluorescent staining (A, C, E, and G) relative to DAPI staining (B, D, F,
and H) in E10.5 littermate controls (A–D) and VEtTAxTetOS-dnMAML AVC (E–H). Boxes in (A) and (E) are regions that have been enlarged and presented as (C)
and (D) and (G) and (H).
(I) Intensity of immunofluorescence staining of GUCY1B3 relative to DAPI intensity, number of nuclei, or CD31 intensity (only EC staining quantified) is shown
(*p = 0.005) (n = 14 littermate control and 4 VEtTAxTetOS-dnMAML-GFP embryos; three sections per embryo were used for quantification).
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Developmental Cell
Notch Activates the NO Pathway in the AV CanalNotch-Induced Activin A Activates eNOS
and Promotes EndMT
To identify the paracrine factor responsible for NO induction in
the developing AVC that is regulated by Notch, we used gene
ontology classifications to select ten secreted factors as
candidate genes that were present both in the EC NICDmicroar-
ray and the AVC transcriptome data sets (Figure 4A). Using
RT-qPCR of NICD-transduced ECs, parental ECs cocultured
with Notch ligand-expressing (Jag1, Dll4) ECs, and vector-trans-
duced ECs, we validated Inhibin b A (INHBA), the gene that
encodes the subunits of the homodimer Activin A, and Insulin
Growth Factor 2 (IGF2), as two factors that were induced by
both NICD and ligand activation of Notch. To confirm that the
products of these genes were secreted, we measured protein
concentrations of Activin A and IGF2 by ELISA in serum-free
NICD-conditioned medium. We did not detect IGF2 protein
(data not shown), but Activin A was significantly increased in
NICD-conditioned medium compared to the empty vector
conditioned medium (9.11 ± 0.28 versus 0.05 ± 0.01 ng/ml
[p = 0.001], respectively) (Figure 4B). By RT-qPCR we confirmed
that ligand-mediated induction of INHBA was Notch dependent
because either Jag1- or Dll4-induced INHBA expression was
inhibited by a g-secretase inhibitor (DAPT) (p = 0.005; Figures
4C and 4D). In contrast, TGFb1 had no effect on INHBA expres-
sion (Figure S3A). One conserved putative RBPJ-binding site
located in intron 1 of human INHBA was identified (+1018 bp
from TSS), and anti-Flag ChIP-qPCR confirmed RBPJ binding
to the human INHBA promoter in ECs transduced with Flag-
RBPJ relative to the empty vector (2.0 ± 0.1-fold enrichment;
p = 0.05) (Figure 4E). To assay Inhba expression in vivo, E9.5,
E10.5, and E11.5 AVCs and whole hearts were harvested for
RT-qPCR. mRNA of Inhba and its receptors (Acvr2a, Acvr2b,
Acvr1b, and Acvr1c) was detected in the AVC from E9.5 to
E11.5, with a significant increase in Inhba expression at E9.5
and E10.5 in the AVC compared to the whole heart (p = 0.05;
Figures 4F–4H). To confirm that Inhba is a target gene of
Notch in vivo, we performed in situ hybridization on E10.5
VEtTAxTetOS-dnMAML-GFP and littermate controls, which
showed a marked decrease in Inhba expression following Notch
blockade (Figure S3B). Collectively, these data indicate that
Notch activation drives expression of INHBA and production of
the INHBA homodimer, Activin A.
To determine whether Activin A is capable of activating eNOS,
parental ECs were treated with recombinant Activin A. eNOS
activation (as determined by anti-phospho-eNOS-Ser1177
immunoblotting) was detected as early as 15 min following
Activin A stimulation (Figure 5A). Activin A stimulated eNOS
activation through PI3K/Akt, because inhibitors targeting either
PI3K (LY294002, 10 mM) or Akt (Triciribine, 10 mM) blocked
eNOS phosphorylation (Figure 5B). Activin A significantly(J) Quantitative analysis of EndMT in AVC explants from E9.5 wild-type mice tr
determined by automated image analysis 48 hr postexplant.
(K) AVC explants from E9.5 wild-type mice were lentivirally transduced with two d
distance migrated by cells emanating from the edge of the AVC explant normalize
with Acta2 immunostaining for (J) and (K).
(L and M) ODQ (50 mg/kg) was administered intraperitoneally 24 hr prior to co
quantifying the number of nuclei relative to the area of the AVC (n = 10, for e
shown in (M).
DevelopinducedNO accumulation, as determined by theGriess reaction,
and this induction of NO was abolished when ECs were trans-
duced with a dnAkt (p = 0.05; Figure 5C).
To determine whether an eNOS-activating factor is secreted
from Notch-activated cells, we treated ECs with NICD-condi-
tioned medium and immunoblotted cell lysates for phospho-
eNOS-Ser1177. We detected eNOS activation as early as
15 min following stimulation compared to the empty vector
control (Figure 5D). eNOS activation was associated with Akt
activation (p-Akt) (Figure 5D). Pretreatment with LY294002
(10 mM), Triciribine (10 mM), or a neutralizing anti-Activin A
antibody (5 ng/ml) blocked the ability of NICD-conditioned
medium to activate eNOS (Figure 5E). Furthermore, treating
dnAkt-transduced ECs with NICD-conditioned medium failed
to activate eNOS (Figure 5F), suggesting an Akt-dependent
activation. We thus conclude that NICD-conditioned medium
activates eNOS via a PI3K/Akt mechanism through the induction
and secretion of Activin A.
To confirm the direct role of Activin A-induced NO in cardiac
cushion EndMT, AVC explants treated with L-NAME (50 mM; p <
0.05), LY294002 (10 mM; p < 0.05), or Triciribine (10 mM; p <
0.05) showed significant inhibition of EndMT compared to
vehicle treatment (Figures 6A and S4). Moreover, AVC isolated
from eNOS/ mice exhibited pronounced decrease in EndMT
compared to wild-type AVC (p < 0.05; Figure 6B). Similarly,
neutralizing anti-Activin A antibody (5 ng/ml) also inhibited
EndMT in AVC explants compared to the IgG control (p < 0.05;
Figures 6C and S5). Significant EndMT inhibition was also
observed in AVC treated with short-hairpin lentivirus targeting
Inhba compared to vector control (p < 0.05; Figures 6D and S5).
These data support a model where Notch-induced Activin A
stimulates NO synthesis via eNOS activation to promote EndMT.
DISCUSSION
In the developing embryo, the heart is the first organ to
form. EndMT commences in the AVC at E9.5 with the
cellularized cushions eventually giving rise to the membranous
interventricular septum and the heart valves (High and Epstein,
2008a; Niessen and Karsan, 2008). Dysregulation of the Notch
signaling pathway is associated with various cardiovascular
anomalies and has been found to be essential for EndMT during
AVCdevelopment (Timmerman et al., 2004; reviewed in High and
Epstein, 2008a; Niessen and Karsan, 2008). However, very few
Notch target genes that facilitate cardiovascular development
have been reported. Notch signaling can induce EndMT by
induction of transcription factors Snail (Luna-Zurita et al., 2010;
Timmerman et al., 2004) and Slug (Niessen et al., 2008; Noseda
et al., 2004) and regulating of TGFb signaling via Smad3 in the
developing AVC (Fu et al., 2009). In this study, we show thateated with BAY41-2272 (10 mM), DAPT (10 mM), ODQ (10 mM), or vehicle as
istinct shGucy1b3 constructs (#1 & #2) or vector control. Results represent the
d to the area of the AVC explant (*p < 0.001). See also Figure S3 for correlation
llection of E9.5–E11.5 embryos (L). Cellularity of the AVC was determined by
ach time point; *p = 0.05, **p = 0.002), and representative micrographs are
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Figure 3. Notch Activation Results in NO Production in a Cell Nonautonomous Fashion
(A) Coculture of Notch ligand-expressing (Jag1-YFP or Dll4-YFP), NICD-YFP-expressing, or vector-YFP ECs with parental ECs induces NO as visualized by
DAR4M-AM fluorescence (red). YFP fluorescence (green) highlights the transduced cells, which represent either ligand-expressing, NICD-expressing, or vector-
transduced ECs, cocultured with the non-YFP parental ECs. The pan-NOS inhibitor L-NAME (50 mM) was used as a control to confirm NOS dependence of
NO production (lower panels).
(B) Mean nitrite levels as measured by the Griess reaction normalized to the total amount of protein in Jag1, Dll4, or vector-transduced ECs cocultured with
parental ECs treated with either L-NAME (50 mM) or vehicle (n = 5; *p = 0.002).
(C) Mean cGMP levels normalized to the total amount of protein in Jag1, Dll4, or vector-transduced ECs cocultured with parental ECs (n = 7; *p = 0.05).
(D–F) Induction of NO and downstream activation of sGC in ECs treated with NICD-conditioned medium. NO level and activity at different times
following NICD-conditioned medium exposure were assayed by DAR4M-AM staining (D), Griess reaction (E; n = 4; *p = 0.05), and cGMP ELISA (F; n = 4;
*p = 0.05).
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Developmental Cell
Notch Activates the NO Pathway in the AV CanalNotch promotes EndMT by autocrine activation of NO signaling.
Notch activation induces expression of the two components of
the heterodimeric sGC,Gucy1a3 andGucy1b3, in the transition-
ing endocardium. In addition, Notch-activated ECs secrete
Activin A, leading to activation of eNOS and release of NO by
a PI3K/Akt-dependent mechanism. Recent findings support
a role for Akt in promoting EndMT in the AVC (Feng et al.,
2010; Meadows et al., 2009).
Although Gucy1a3 or Gucy1a2 single gene-targeted mice
exhibit only a mild phenotype (Mergia et al., 2006),Gucy1b3-tar-
geted mice are hypertensive and demonstrate platelet defects,
and impaired peristalsis (Friebe et al., 2007; Groneberg et al.,
2010). Thus, it is thought that Gucy1a2 and Gucy1a3 can
compensate for each other in the context of embryonic gene
targeting, but Gucy1b3 is the essential partner for both Gucy1a
isoforms. Although NO signaling in the vasculature is best recog-
nized for relaxing vascular smooth muscle through activation of
sGC, Gucy1a3 and Gucy1b3 proteins have also been shown to
play a role in cell migration during angiogenesis in zebrafish
(Pyriochou et al., 2006). Our findings reported here are in keeping
with a role for sGC in promoting endothelial migration and
invasion in the context of EndMT during AVC development, as
seen in angiogenesis. Indeed, the process of angiogenesis
requires that ECs delaminate and invade the underlying matrix
similar to the process of EndMT.
Homozygous eNOS mutant mice have been shown to exhibit
several cardiovascular defects, including bicuspid aortic valves
(Aicher et al., 2007; Feng et al., 2002; Lee et al., 2000). Interest-
ingly, heterozygous NOTCH1mutations seen in humans are also
associated with bicuspid aortic valves (Garg et al., 2005).
Previous studies have shown that various signaling pathways
can activate eNOS, in particular, shear stress is a major activator
of NO generation (Cheng et al., 2005; Ziegler et al., 1998).
Although it remains controversial whether heart development
commences prior to blood flow (DeHaan, 1965) or whether blood
flow is required to initiate the process (Hove et al., 2003; Nonaka
et al., 2002), it is clear that narrowing at the AVC leads to
increased shear stress at the endocardium at that location
(Hove et al., 2003). Shear stress activates eNOS through phos-
phorylation of residue Ser1177 by Akt (Dimmeler et al., 1999;
Fulton et al., 1999; Michell et al., 1999). Recent studies have
suggested that shear stress also activates Notch signaling by
inducing Notch receptors and ligands (Masumura et al., 2009;
Wang et al., 2007). Thus, it is tempting to speculate that shear
stress-induced NO may be in part through a Notch-dependent
mechanism.
How then does Notch activate eNOS? Our data suggest that
INHBA is a direct target gene of Notch, and that the INHBA
homodimer, Activin A, is increased in NICD-conditionedmedium
(Figure 4B). Our studies confirm that Inhba is highly expressed in
the AVC at E9.5 and E10.5 compared to thewhole heart, and that
Activin A appears to be the major paracrine factor in NICD-
conditioned medium that activates the PI3K/Akt pathway and
eNOS. Although members of the TGFb superfamily are known(G–I) In vivo NO levels were measured by DAR4M-AM fluorescence (25 mmol/kg
AVC from littermate control and VEtTAxTetOS-dnMAML-GFP embryos following
are shown where the AVC border is outlined with white dotted lines. Mean DAR4M
shown (n = 4–7 with minimum 3 embryos per group; *p% 0.05).
Developcritical factors in EndMT in the AVC (Nakajima et al., 2000), our
results show a requirement for Activin A in particular.
Based on our results, we propose a model (see Graphical
Abstract) where Notch-activated cells that become EndMT
committed begin to lose cell-cell junctions (Niessen et al.,
2008) and increase sGC levels. As these cells start to invade
and migrate into the cardiac cushion, Notch-induced secretion
of Activin A may diffuse into the surrounding endocardium to
activate eNOS and induce NO synthesis. NO binding to sGC in
the ECs committed to mesenchymal transition then promotes
cell migration and invasion.
EXPERIMENTAL PROCEDURES
Animals
Male and female C57Bl/6J and eNOS null mice weighing between 25 and 35 g
were purchased from Jackson Laboratories (Bar Harbor, ME). TetOS-dnMAML
transgenic mice have been previously described (Fu et al., 2009). The VE-cad-
herin-tTA (VEtTA) strain was a gift from L. Benjamin, Harvard Medical School
(Boston, MA) (Meadows et al., 2009). Suppression of dnMAML expression
was achieved by administering either tetracycline (50 mg/ml) or doxycycline
(50 mg/ml) in the drinking water. All animal protocols were approved by the
Animal Care Committee of the University of British Columbia (Vancouver,
British Columbia, Canada).
Reagents
Rabbit anti-GUCY1B3 was acquired from Abcam (Cambridge, MA). Rabbit
anti-p-eNOS-S1177, rabbit anti-eNOS, rabbit anti-pAkt, rabbit anti-Akt, rabbit
anti-cleaved Notch1 antibody, and LY294002 inhibitor were acquired fromCell
Signaling Technology (Beverly, MA). Rat anti-RBPJ (RBPJk-T6719) was
acquired from the Institute of Immunology, Tokyo (Hamaguchi et al., 1992).
Rat anti-mouse CD31/PECAM antibody and type I collagen were acquired
from BD Sciences (Franklin Lakes, NJ). Rabbit anti-GFP and Alexa Fluor
secondary antibodies were acquired from Invitrogen (Carlsbad, CA). DAPI,
mouse monoclonal antibody against the FLAG epitope (M2), mouse
monoclonal antibody against Acta2, ODQ, L-NAME, Insulin/Transferrin/Sele-
nium (ITS) supplement, and mouse anti-tubulin were purchased from Sigma-
Aldrich (St. Louis, MO). DAR4M-AM was acquired from Millipore (Billerica,
MA). The Griess reagent was obtained from Promega (Madison, WI).
Neutralizing anti-Activin A antibody, Cyclic-GMP assay kit, and human Activin
A (INHBA) Quantikine ELISA kit were purchased from R&D Systems (Minnea-
polis, MN). Human IGF2 ELISA kit was obtained from Diagnostic Systems
Laboratories (Webster, TX). All primers were acquired from Integrated DNA
Technologies (San Diego, CA). BAY41-2272 compound was purchased from
Alexis/Enzo Life Sciences (Farmingdale, NY). DAPT and Akt inhibitor Triciribine
were acquired from Calbiochem/EMD Chemicals (Gibbstown, NJ).
Cell Culture and RNA Interference
EC lines were obtained and cultured as previously described (Noseda et al.,
2004). ECs were transduced using the retroviral vectors MIY, MIY-Jag1,
MIY-Dll4, MIY-NICD, pLNCX, pLNCX-FLAG-RBPJ, MSCVNeo, and
MSCVNeo-NICD as previously described (Niessen et al., 2008). pLNCX-
AktDN-Myc (AktDN has been mutated to remove three activating phosphory-
lation sites, K179M, T308A, and S473A, and acts as a dn molecule) was a kind
gift from Dr. Issei Komuro. Short hairpin RNA targeting RBPJ,Gucy1b3, Inhba,
or random sequences were acquired from Open Biosystems (Huntsville, AL),
or previously generated in-house (see Table S2) (Niessen et al., 2008). ECs
were transduced with MSCVNeo-NICD or MSCVNeo to generate conditioned
medium. All cells were starved in serum-free MCDB 131medium for 24 hr prior
to collection of conditioned medium. Conditioned medium was filtered withinjected intraperitoneally 1 hr prior to collecting embryos) in E10.25 and E10.5
24 hr of Notch inhibition (dnMAML induction). Representative sagittal sections
-AM staining intensities normalized to total AVC area (H) or total EC area (I) are
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Figure 4. Notch Activation Induces INHBA Expression and Activin A Release
(A) Potential eNOS-activating factors were evaluated by RT-qPCR in Notch-activated ECs. ECs were transduced with Jag1, Dll4, NICD, or empty vector. Results
are shown as fold enrichment over the vector control (n = 3; *p < 0.05).
(B) Activin A concentrations in empty vector- or NICD-transduced EC-conditioned medium were evaluated by ELISA and are shown (n = 9; *p = 0.001).
(C) Expression of INHBA in Notch ligand-activated ECs in the presence or absence of DAPT was evaluated by RT-qPCR, and data are shown as fold enrichment
over the vector control (n = 3; *p < 0.0005).
(D) Expression of INHBA induced by Notch ligand was evaluated in flow-sorted Jag1, Dll4, or vector (YFP+), and cocultured parental ECs (YFP) are shown as
fold enrichment over the vector control (n = 3, *p < 0.05).
(E) RBPJ occupancy on a conserved putative RBPJ-binding site of human INHBAwas examined by anti-Flag ChIPwith IgG as negative control in ECs transduced
with either Flag-RBPJ or empty vector. Fold enrichment is shown, determined as a percentage of input DNA and normalized to the empty vector anti-Flag ChIP
(n = 3; *p = 0.05).
(F–H) RT-qPCR was used to analyze expression of Inhba, Inhbb, and their cognate receptors (Acvr1 and Acvr2) at E9.5, E10.5, and E11.5 in the AVC and whole
heart. Expression of genes in AVC is shown as fold enrichment over the whole heart at the same developmental stage (n = 3; *p = 0.05). Figure S4 shows Inhba
expression by in situ hybridization.
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Notch Activates the NO Pathway in the AV Canala 0.45 mm filter and applied onto parental ECs, which were also starved in
serum-free MCDB 131. All inhibitors and recombinant Activin A were added
1 hr prior to conditioned medium treatment. Cell lysates were collected in
RIPA buffer as previously described (Fu et al., 2009).296 Developmental Cell 21, 288–300, August 16, 2011 ª2011 ElsevieMicroarray and Analysis Software
HUVECs were either transduced with MIY-NICD or MIY vector control. The
cells were sorted for YFP, and RNA was extracted using TRIzol (Invitrogen)
and analyzed by the Affymetrix Human Genome U133 Plus 2.0 Array (NCBIr Inc.
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Figure 5. Notch-Induced Activin A Activates eNOS via the PI3K/Akt Pathway
(A) ECs were treated with either recombinant Activin A (5 ng/ml) or vehicle (0.2%BSA in PBS) for various times, and cell lysates were analyzed by immunoblotting
for p-ENOS, ENOS, and Tubulin.
(B) Parental ECswere treatedwith recombinant Activin A (5 ng/ml) in the presence of vehicle (DMSO), PI3K inhibitor (LY294002, 10 mM), or Akt inhibitor (Triciribine,
10 mM) for 15 min, and cell lysates were analyzed by immunoblotting for p-ENOS, ENOS, p-Akt, Akt, and Tubulin.
(C)Mean nitrite levels asmeasured by theGriess reaction normalized to the total amount of protein in dnAkt or vector-transduced ECs treatedwith Activin A (n = 5;
*p = 0.05).
(D) Parental ECswere treatedwith conditionedmedium collected from either NICD-transduced or empty vector-transduced ECs for various times and cell lysates
analyzed by immunoblotting using antibodies against the protein shown.
(E) Parental ECs were left untreated (UT), or treated with conditioned medium from either empty vector (V) or NICD (N)-transduced ECs in the presence of vehicle
(DMSO), PI3K inhibitor (LY294002, 10 mM), or Akt inhibitor (Triciribine, 10 mM) for 15min and examined by immunoblotting (left). Alternatively, conditionedmedium
from either empty vector (V)- or NICD (N)-transduced ECs was used to treat parental ECs in the presence of neutralizing anti-Activin A antibody or an IgG isotype
control antibody (right).
(F) ECs transduced with either dnAkt or vector alone were treated with conditioned medium from either empty vector (V)- or NICD (N)-transduced ECs.
Developmental Cell
Notch Activates the NO Pathway in the AV CanalGEO accession number: GSE29850). Results were analyzed using the
GCRMA algorithm to identify genes with a minimum of 2-fold induction as
described (Harrington et al., 2008). SAGE libraries of the developing AVC
were generated as part of the Mouse Atlas Project (Siddiqui et al., 2005)
(www.mouseatlas.org). Gene ontology analysis was conducted using the
DAVID/EASE program (Dennis et al., 2003).
RNA Collection and RT-qPCR
Total RNA from cultured cells or manually dissected C57BL/6J embryonic
hearts was isolated by TRIzol isolation (Invitrogen), and cDNA was made as
previously described (Noseda et al., 2004). RT-qPCR was carried out using
the SYBR green (Applied Biosystems, Foster City, CA) method on an Applied
Biosystems 7900HT with primers listed in Table S2. All primers targeting tran-
scripts spanned exon-exon junctions were designed using the Roche Probe-
Library website (Indianapolis, IN).
ChIP
ECs were transduced with pLNCX or pLNCX-FLAG-RBPJ, and the ChIP assay
was performed as previously described (Noseda et al., 2004). ChIP DNA was
amplified for RBPJ-binding sites in human GUCY1A3,GUCY1B3, INHBA, and
Hey1 promoters using primers listed in Table S2. Binding enrichment to theDeveloprelevant promoter was calculated using the percentage of ChIP DNA (relative
to input chromatin) normalized to the vector control.
Immunofluorescence Staining
Tissues were fixed in 4% paraformaldehyde (PFA) overnight, dehydrated in
30% sucrose/phosphate-buffered solution (PBS), and embedded in OCT
(Sakura, Japan). Ten micron cryosections were collected and stored at
80C until staining. For immunofluorescence staining, sections were washed
with PBS and incubated overnight with primary antibody in staining buffer
(4% calf serum/0.1%Triton X-100/PBS). Slides were then washed with PBS
and incubated at room temperature with secondary antibodies in staining
buffer for 1 hr. Slides were then washed with PBS, and nuclei were stained
with DAPI and mounted with ProLong Gold Antifade (Invitrogen). All AVC
micrographs were acquired using an Axiovert S100 Zeiss microscope. Images
were captured using NorthernEclipse software and quantifications performed
using ImageJ (NIH).
AVC Explant Assay
AVC explant assays were performed as previously described (Niessen et al.,
2008). Explants were cultured for 48 hr with various inhibitors or activators in
1% FBS/0.5% ITS/DMEM: g-secretase inhibitor (DAPT, 10 mM), sGC inhibitormental Cell 21, 288–300, August 16, 2011 ª2011 Elsevier Inc. 297
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Figure 6. The Notch-Activin A-PI3K/Akt-eNOS Axis Is Necessary for AVC EndMT
Quantitative analysis of EndMT in AVC explants from E9.5 AVC.
(A) Nitric oxide signaling-induced EndMT was evaluated by treating AVC with inhibitors L-NAME (50 mM), LY294002 (10 mM), Triciribine (10 mM), or DMSO
(vehicle).
(B) AVCs from eNOS/ mice or wild-type controls were quantified for EndMT.
(C) The requirement for Activin A in EndMT was evaluated by treating AVC with either anti-Activin A neutralizing antibody (0.5 ng/ml) or isotype control IgG.
(D) Alternatively, wild-type AVCs were lentivirally transduced with shInhba to knock down Inhba, or a vector control. Results represent the distance migrated of
cells invading the collagen matrix from the edge of the AVC explant normalized to the area of the AVC tissue (*p = 0.05). See also Figure S5 for correlation with
Acta2 staining.
Developmental Cell
Notch Activates the NO Pathway in the AV Canal(ODQ, 10 mM), NO-independent sGC activator (BAY41-2272, 10 mM), NOS
inhibitor (L-NAME, 50 mM), PI3K inhibitor LY294002 (10 mM), Akt inhibitor Tri-
ciribine (10 mM), anti-Activin A neutralizing antibody (0.5 mg/ml), isotype IgG
control (0.5 mg/ml) or purified lentivirus targeting Gucy1b3, Inhba or vector
control. Explants were fixed with 4% PFA and then stained for Acta2 and
DAPI. All immunofluorescence micrographs were acquired using an Axioplan2
Zeiss microscope. The number and distance of migrating cells were analyzed
as previously described (Niessen et al., 2008). Briefly, Acta2 or DAPI staining
pixels were summed up for each pixel that was closest to the AVC explant.
This was repeated by extending one pixel away from the explant until all
migrating and invading cells were accounted for. All readings were then
normalized to size of AVC explant and plotted over distance (Supplemental
Experimental Procedures). To ensure that the migrating/invading cells
comprised mesenchymal cells, all explants were also stained with the
mesenchymal marker, Acta2, and the areas of Acta2 and DAPI staining were
correlated (Supplemental Experimental Procedures, and Figures S3 and S5).
Data Analysis
All data are shown as the mean ± SEM of multiple experiments. All statistical
analyses were calculated using two-tailed Student’s t test and were consid-
ered to be statistically significant at p < 0.05.
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